<code id='D556B4AEA1'></code><style id='D556B4AEA1'></style>
    • <acronym id='D556B4AEA1'></acronym>
      <center id='D556B4AEA1'><center id='D556B4AEA1'><tfoot id='D556B4AEA1'></tfoot></center><abbr id='D556B4AEA1'><dir id='D556B4AEA1'><tfoot id='D556B4AEA1'></tfoot><noframes id='D556B4AEA1'>

    • <optgroup id='D556B4AEA1'><strike id='D556B4AEA1'><sup id='D556B4AEA1'></sup></strike><code id='D556B4AEA1'></code></optgroup>
        1. <b id='D556B4AEA1'><label id='D556B4AEA1'><select id='D556B4AEA1'><dt id='D556B4AEA1'><span id='D556B4AEA1'></span></dt></select></label></b><u id='D556B4AEA1'></u>
          <i id='D556B4AEA1'><strike id='D556B4AEA1'><tt id='D556B4AEA1'><pre id='D556B4AEA1'></pre></tt></strike></i>

          Home / hotspot / entertainment

          entertainment


          entertainment

          author:comprehensive    Page View:67
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In